- Rojas, J., de Lazzari, E., Negredo, E., Domingo, P., Paredes, R., Clotet, B. , et al. (2021). Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV, 8(8), E463-E473. https://doi.org/10.1016/S2352-3018(21)00100-4
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial
on 13 d'octubre de 2021
with No hi ha comentaris
Deixa un comentari